We are live on
!
Find out more
HP
HealthInvest Partners Portfolio holdings
AUM
$372M
1-Year Est. Return
59.89%
This Fund
S&P 500
This Quarter
Est. Return
-5.85%
1 Year Est. Return
+59.89%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$43.4M
AUM Growth
-$19.4M
(-31%)
Cap. Flow
-$17.7M
Cap. Flow
% of AUM
-40.78%
Top 10 Holdings %
Top 10 Hldgs %
88.87%
Holding
14
New
2
Increased
4
Reduced
6
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Viatris
VTRS
|
+$3.4M |
| 2 |
OPNT
Opiant Pharmaceuticals, Inc. Common Stock
OPNT
|
+$3.1M |
| 3 |
Aurinia Pharmaceuticals
AUPH
|
+$2.57M |
| 4 |
Utah Medical Products
UTMD
|
+$2.56M |
| 5 |
LJPC
La Jolla Pharmaceutical Company
LJPC
|
+$2.17M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ironwood Pharmaceuticals
IRWD
|
+$8.93M |
| 2 |
McKesson
MCK
|
+$6.4M |
| 3 |
Cardinal Health
CAH
|
+$5.67M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$2.89M |
| 5 |
Cigna
CI
|
+$2.58M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Utah Medical Products
UTMD
$230M
| $7.39M | 17.03% |
86,000
+30,000
| +54% | +$2.56M |
|
|
LJPC
2
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $4.04M | 9.3% |
1,265,000
+558,000
| +79% | +$2.17M |
|
3
Harmony Biosciences
HRMY
$2.25B
| $3.71M | 8.55% |
76,000
-44,000
| -37% | -$1.98M |
|
|
4
Cigna
CI
$72.4B
| $3.69M | 8.5% |
14,000
-10,000
| -42% | -$2.58M |
|
5
Gilead Sciences
GILD
$168B
| $3.58M | 8.26% |
58,000
-40,000
| -41% | -$2.48M |
|
|
6
Bristol-Myers Squibb
BMY
$135B
| $3.39M | 7.81% |
44,000
-38,000
| -46% | -$2.89M |
|
7
Biogen
BIIB
$30.8B
| $3.26M | 7.52% |
16,000
-12,000
| -43% | -$2.45M |
|
|
8
McKesson
MCK
$97.2B
| $3.26M | 7.52% |
10,000
-20,000
| -67% | -$6.4M |
|
|
9
Viatris
VTRS
$20.6B
| $3.25M | 7.48% |
+310,000
| New | +$3.4M |
|
10
Zevra Therapeutics
ZVRA
$622M
| $2.99M | 6.89% |
670,000
+415,000
| +163% | +$1.89M |
|
|
OPNT
11
DELISTED
Opiant Pharmaceuticals, Inc. Common Stock
OPNT
| $2.52M | 5.8% |
210,000
+192,000
| +1,067% | +$3.1M |
|
|
12
Aurinia Pharmaceuticals
AUPH
$1.92B
| $2.31M | 5.33% |
+230,000
| New | +$2.57M |
|
|
13
Cardinal Health
CAH
$54.7B
| – | – |
-100,000
| Closed | -$5.67M |
|
|
14
Ironwood Pharmaceuticals
IRWD
$709M
| – | – |
-710,000
| Closed | -$8.93M |
|
Similar funds
KP
TCM
SAAM
PAA
PC
BOCH
GIP
PC
HealthInvest Partners's Q2 2022 Portfolio in Review
As of Q2 2022, HealthInvest Partners held 14 positions worth $43.4M, down 31% from $62.8M the previous quarter. Its ten largest holdings account for 89% of the portfolio.
HealthInvest Partners withdrew a net $17.7M in Q2 2022, closing 2 positions and reducing 6 holdings. Its most notable exit was Ironwood Pharmaceuticals, an estimated $8.93M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, HealthInvest Partners opened a new position in Viatris worth $3.25M.
- HealthInvest Partners's largest Q2 2022 buy was Viatris: 310,000 shares worth $3.25M.
- HealthInvest Partners added most to Opiant Pharmaceuticals, Inc. Common Stock in Q2 2022, an estimated $3.1M increase.
- HealthInvest Partners's biggest Q2 2022 reduction was McKesson, cutting an estimated $6.4M.
- HealthInvest Partners fully exited Ironwood Pharmaceuticals in Q2 2022, selling an estimated $8.93M.
- HealthInvest Partners's ten largest holdings make up 89% of its $43.4M portfolio in Q2 2022.
- HealthInvest Partners opened 2 new positions and closed 2 in Q2 2022.
- HealthInvest Partners's portfolio value fell 31% quarter-over-quarter to $43.4M.
Based on HealthInvest Partners's 13F filing for Q2 2022, filed 8 Jul 2022.